Evaluating a new vaccine for Epstein Barr virus in healthy adults
Official title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V350A and V350B in Healthy Participants.
Run by Merck Sharp & Dohme LLC · NCT06655324 · Data updated 2026-11-12
This study is testing two new vaccines for the Epstein Barr virus in healthy adults to see if they are safe and effective at preventing related diseases.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 12 Years to 30 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Merck Sharp & Dohme LLC Industry-sponsored |
| Locations | 9 sites (Glendale, California and 8 other locations) |
| Status | Recruiting |
| Started | December 5, 2024 |
| Main results expected | July 17, 2028 |
| Study ends | July 17, 2028 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT06655324 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are healthy adults aged 18 to 65 with a BMI between 18 and 35.
✕Probably not a fit
Patients with a history of infectious mononucleosis or those with immunosuppressive conditions will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the safety, tolerability, and immunogenicity of two new vaccine candidates, V350A and V350B, in healthy adult participants. The research focuses on understanding how well these vaccines can be tolerated and their potential effectiveness in preventing diseases associated with the Epstein Barr virus (EBV). Participants will be randomly assigned to receive either the vaccine or a placebo, and their health will be monitored throughout the study. The goal is to gather important data that could lead to new preventive measures against EBV-related diseases.
Why it matters
Potential benefit: If successful, this study could lead to a new vaccine that helps prevent diseases linked to Epstein Barr virus.
How similar studies have gone: While this approach is novel in the context of EBV vaccines, similar vaccine studies have shown promise in other viral infections.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: The key inclusion criteria include but are not limited to the following: * Is in good health before randomization. * Has a body mass index between 18 and 38 kg/m\^2, inclusive, for adults 18-30; has a body mass index between 15 and 38 kg/m\^2, inclusive, for adolescents 12-17. Exclusion Criteria: The key exclusion criteria include but are not limited to the following: * Has a confirmed or suspected case of infectious mononucleosis within 12 months prior to enrollment. * Has any immunosuppressive medical condition or receive any immunosuppressive therapy.
Where it's running
-
Alliance for Multispecialty Research, LLC ( Site 0008)
Kansas City, Missouri, United States Recruiting -
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0016)
Springfield, Missouri, United States Recruiting -
Velocity Clinical Research Lincoln ( Site 0004)
Lincoln, Nebraska, United States Recruiting -
Velocity Clinical Research, Omaha ( Site 0005)
Omaha, Nebraska, United States Recruiting -
Remington-Davis, Inc. ( Site 0017)
Columbus, Ohio, United States Recruiting -
Lynn Health Science Institute ( Site 0010)
Oklahoma City, Oklahoma, United States Recruiting
Show 3 more locations
-
California Clinical Trials Medical Group managed by PAREXEL ( Site 0011)
Glendale, California, United States Completed -
QPS-MRA, LLC ( Site 0012)
South Miami, Florida, United States Active not recruiting -
Alliance for Multispecialty Research, LLC ( Site 0009)
Knoxville, Tennessee, United States Active not recruiting
Study contacts
- Study coordinator: Toll Free Number
- Email: Trialsites@msd.com
- Phone: 1-888-577-8839
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.